Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY6K siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
LY6K siRNA is a research-grade small interfering RNA (siRNA) designed to silence the expression of the Lymphocyte Antigen 6 Complex Locus K (LY6K) gene. LY6K is a glycosylphosphatidylinositol (GPI)-anchored protein that is frequently overexpressed in various malignancies, including cervical, lung, and breast cancers, where it promotes cell proliferation, migration, and invasion. By targeting the LY6K mRNA transcript for degradation via the RNA interference (RNAi) pathway, LY6K siRNA inhibits the production of the LY6K protein, thereby modulating downstream signaling pathways such as TGF-β and EGF. While widely used in preclinical oncology research to validate LY6K as a therapeutic target, LY6K siRNA is currently utilized as a laboratory tool rather than a clinical-stage therapeutic candidate.
- Other names
- LY6K small interfering RNALY-6K small interfering RNALY 6K small interfering RNALymphocyte Antigen 6 Complex Locus K siRNA
02
Targets
LY6K (Lymphocyte antigen 6 complex locus protein K)
Beyond the preview
Go deeper on LY6K siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY6K siRNA.